Phase III Clinical Study of JTE-052 - 52-week Long-term Study in Patients with Atopic Dermatitis

Japan Tobacco Inc.0 个研究点目标入组 352 人开始时间: 2017年3月31日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方: Japan Tobacco Inc.
入组人数: 352

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

This study confirmed that dermal application of JTE-052 ointment 0.5% twice daily for 52 weeks was safe and well tolerated in Japanese patients with atopic dermatitis. The efficacy in improving atopic dermatitis was maintained without attenuation during long-term application of JTE-052 ointment 0.5%.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 16age old 至 ot applicable（—）
性别: All

入选标准

•Patients with atopic dermatitis

排除标准

•Patients with active infection at the study drug application site
•Use of topical corticosteroids (strongest or very strong) within 14 days before baseline

研究者

发起方

Japan Tobacco Inc.

相似试验

已完成

3 期

Phase III Clinical Study of JTE-052 Ointment - Long-Term Study of JTE-052 Ointment in Japanese infant Patients with Atopic DermatitisAtopic dermatitis

JPRN-jRCT2080225316Japan Tobacco Inc.22

已完成

3 期

Phase III Study of JTE-052 Ointment in Pediatric Patients with Atopic DermatitisAtopic dermatitis

JPRN-jRCT2080224005Japan Tobacco Inc.137

已完成

3 期

Phase III Clinical Study of JTE-052 - Randomized Controlled and Long-term Extension Study in Patients with Atopic DermatitisAtopic dermatitis

JPRN-jRCT2080223499Japan Tobacco Inc.158

已完成

2 期

Phase II Clinical Study of JTE-052 - Dose finding study in patients with atopic dermatitisAtopic dermatitis

JPRN-jRCT2080222835Japan Tobacco Inc.327

进行中（未招募）

3 期

Phase 3 Clinical Study of JTE-061 Cream - 52-week Long-term Study in Patients with Plaque PsoriasisPlaque psoriasis

JPRN-jRCT2031210254emoto Takanori300